Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)
Carmine De Angelis(Baylor College of Medicine), Grazia Arpino(University of Naples Federico II), Saverio Cinieri(Ospedale A. Perrino), Fabio Puglisi(University of Udine), Emanuela Magnolfi(Accademia di Belle Arti di Frosinone), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Zelmira Ballatore(Presidio Ospedaliero), Anna Maria Mosconi(Azienda Ospedaliera di Perugia), Mario Giuliano(Regione Campania), Lucia Del Mastro(Ospedale Policlinico San Martino), Dario Bruzzese(University of Naples Federico II), V. Leonardi(University of Palermo), Sabino De Placido, Alessandra Fabi(Agostino Gemelli University Polyclinic), Martina Pagliuca(Institut Gustave Roussy), Mauro Mansutti(Hospital Clínico Universitario de Valencia), Roberto Bordonaro(Ospedale Garibaldi)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830